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Abstract
Background: Friedreich’s ataxia (FRDA) is the most common hereditary ataxia among caucasians. The molecular defect in
FRDA is the trinucleotide GAA expansion in the first intron of the FXN gene, which encodes frataxin. No studies have yet
reported frataxin protein and mRNA levels in a large cohort of FRDA patients, carriers and controls.
Methodology/Principal Findings: We enrolled 24 patients with classic FRDA phenotype (cFA), 6 late onset FRDA (LOFA), all
homozygous for GAA expansion, 5 pFA cases who harbored the GAA expansion in compound heterozygosis with FXN point
mutations (namely, p.I154F, c.482+3delA, p.R165P), 33 healthy expansion carriers, and 29 healthy controls. DNA was
genotyped for GAA expansion, mRNA/FXN was quantified in real-time, and frataxin protein was measured using lateral-flow
immunoassay in peripheral blood mononuclear cells (PBMCs). Mean residual levels of frataxin, compared to controls, were
35.8%, 65.6%, 33%, and 68.7% in cFA, LOFA, pFA and healthy carriers, respectively. Comparison of both cFA and pFA with
controls resulted in 100% sensitivity and specificity, but there was overlap between LOFA, carriers and controls. Frataxin
levels correlated inversely with GAA1 and GAA2 expansions, and directly with age at onset. Messenger RNA expression was
reduced to 19.4% in cFA, 50.4% in LOFA, 52.7% in pFA, 53.0% in carriers, as compared to controls (p,0.0001). mRNA levels
proved to be diagnostic when comparing cFA with controls resulting in 100% sensitivity and specificity. In cFA and LOFA
patients mRNA levels correlated directly with protein levels and age at onset, and inversely with GAA1 and GAA2.
Conclusion/Significance: We report the first explorative study on combined frataxin and mRNA levels in PBMCs from a
cohort of FRDA patients, carriers and healthy individuals. Lateral-flow immunoassay differentiated cFA and pFA patients
from controls, whereas determination of mRNA in q-PCR was sensitive and specific only in cFA.
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Introduction
Friedreich’s ataxia (FRDA), an autosomal recessive neurode-
generative disorder, is the most common hereditary ataxia among
Caucasians [1]. The disease is characterized by gait and limb
ataxia, dysarthria, usually absent tendon reflexes, bilateral
Babinski sign, impairment of position and vibratory senses,
scoliosis, and pes cavus [2]. Cardiomyopathy is the predominant
cause of death [3].
The molecular defect in FRDA is the trinucleotide GAA
e x p a n s i o ni nt h ef i r s ti n t r o no ft h eFXN gene [4]. Most patients
are homozygous for this mutation. Two to 5% of patients
harbor a point mutation on one allele and a GAA expansion on
the other allele. The FXN gene encodes a 210 amino acid
mitochondrial protein named frataxin. FXN mRNA was found
to be reduced to 13–30% in FRDA patients, and to 40% in
carriers, as compared to control mRNA [5]. The residual
amount of frataxin protein in FRDA patients varies between 4
and 29% of the level seen in normal control, and shows an
inverse correlation with the size of the GAA1 repeat [6].
Although the exact physiological function of frataxin is not
known, its involvement in iron–sulphur (Fe–S) cluster and heme
biogenesis, iron binding/storage and iron chaperone activity has
been suggested [7,8,9].
To date four studies have precisely quantified frataxin levels
in FRDA patients, carriers or controls. A first study [10]
adopted a lateral flow immunoassay to quantify frataxin in
peripheral blood mononuclear cells (PBMC), cultured lympho-
blasts, and cheek swabs. Standard curves were prepared using
recombinant frataxin (amino acids 56-210). In that study,
frataxin was also determined in lymphoblastoid cell lines from
five controls, four carriers, and seven FRDA patients. The
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total cell protein (range 343–488). Residual protein levels were
64% in carriers, and 29% in FRDA patients and there was
overlap between FRDA patients and carriers. A second study
determined frataxin in cheek swabs by lateral flow immunoassay
[11]. FRDA patients showed 20.9%, and carriers 50.2% of
frataxin levels of controls. Similar data were obtained in whole
blood samples. A recent quantitative electrochemiluminiscence
assay (ECLIA) [12] measured 7.9–11.9 in PBMC from five
controls and 1.1–4.8 pg/mg frataxin in 11 FRDA patients
(reduction to 27% of controls), and showed no overlap between
the two groups.
Even more recently, the same group showed that frataxin levels
ranged 0.056–0.169 pg/mg protein when assayed using an in-
house enzyme-linked immunosorbent assay (ELISA) [13]. There
was no correlation between frataxin levels, size of GAA repeats,
age, and gender in that study.
The aim of the present study was to combine the determination
of frataxin levels and mRNA expression in PBMCs from a cohort
of consecutive FRDA patient, carriers, and controls, and to
correlate results with genotype and clinical presentation.
Materials and Methods
Study Design
We designed an observational study to examine frataxin levels
in FRDA patients, FRDA carriers, and controls. The local
Ethics Committee of our Institution, ‘‘Comitato Etico per le
Attivita ` Biomediche dell’Universita `d e g l iS t u d id iN a p o l i
Federico II’’, approved the clinical trial (registration number
49/09). All patients gave written informed consent before any
activity linked to the study was started. Patients, carriers, and
controls were consecutively enrolled from March 2009 to April
2010. Patients were divided in the following categories. Classic
FRDA (cFA) was defined as patients with a molecular diagnosis
of FRDA with a number of GAA triplets within the pathological
range on both alleles [4], and an onset before the age of 25
years. Point mutation FRDA (pFA) was defined as patients with
a number of GAA triplets within the pathological range on one
allele, and a point mutation on the other allele. Late onset
Friedreich Ataxia (LOFA) was defined as patients with age at
onset $25 years [14,15] and a molecular diagnosis of FRDA
with a number of GAA triplets within the pathological range on
both alleles. Carriers were selected on an obligate carrier basis.
Controls were randomly enrolled through the site personnel of
our University.
Quantitative analysis of Frataxin with Lateral Flow
Immunoassay
PBMCs were extracted from 30 mL of EDTA anticoagulated
whole blood using LeucosepH tubes (Greiner bio-one, Frick-
enhausen, Germany) and frozen at 280uC until analysis.
PBMCs were lysed and total protein was measured using the
bicinchoninic acid assay. In each well, 7.125 mg of total protein
extract were loaded. Dipsticks were added and processed
following kit instructions. Dried dipsticks were analyzed with
the Hamamatsu ICA-1000 scanner and quantified with
dedicated software. Interpolation was performed on a standard
curve constructed with recombinant human frataxin (extraction
kit, dipsticks and scanner, Mitosciences, Eugene, OR, USA)
[10]. In our hands, lateral flow immunoassay performed well,
with intra-assay and inter-assay coefficients of variability both
,5%.
Molecular analysis of GAA expansion
DNA used for PCR amplification was extracted from venous
blood leukocytes using standard methods. Amplification of normal
and expanded alleles was obtained by PCR procedures previously
described [16]. Triplet Repeat Primed PCR (TP-PCR) was
performed according to the protocol previously described [17].
Briefly, primer sequences used for FRDA TP PCR test were: P1
59-GCTGGGATTACAGGCGCGCGA-39,P 35 9- TACG-
CATCCCAGTTTGAGACG-39,P 45 9-6-FAM TACGCATC-
CCAGTTTGAGACGGAAGAAGAAGAAGAA-
GAAGAA-39. TP-PCR assay was performed in a reaction volume
of 15 ml containing 100 ng genomic DNA, 1.5 mmol/L MgCl2,
10 mmol/L Tris (pH 8.3), 50 mmol/L KCl, 0.8 mmol/L primer
P1, 0.7 mmol/L primer P3, 0.07 mmol/L primer P4, 200 mmol/L
dNTPs each, and 2 units Taq polymerase. The reactions were
subjected to 30 cycles consisting of 94uC for 30 seconds, 60uC for
30 sec, 72uC for 30 sec followed by a 10 min extension at 72uC.
PCR products were incubated at 95uC for 2 min and cooled on ice
before loading and resolved by electrophoresis on an automatic
sequencer (ABI 3500; Applied Biosystems, Foster City, CA). Two
ml of each PCR product were added to 18 ml of formamide
(Applied Biosystems, Foster City, CA) and 0.5 ml of Genescan
400HD (Rox) Size standard (Applied Biosystems). Each sample
underwent TP- PCR three times. The size of the PCR product was
estimated using appropriate DNA molecular marker size standards
(Invitrogen, San Diego, CA, USA) on agarose 0.8% gel stained
with ethidium bromide using ImageQuant TL software in an
ImageQuant 350 molecular imager (GE Healthcare Europe
GmbH, Freiburg, Germany).
Table 1. Demographics and genotyping for all subjects.
Number Age (years)
Onset
(years)
Disease
Duration
(years) GAA1 repeats GAA2 repeats
cFA 27 35612 15682 0 610 7556292 9486254
pFA 5 42.065 9.0643 3 63 9056101 -
LOFA 6 49683 5 . 0 610 14.067 3756127 7536262
Carriers 33 51617 - - 15679 8 3 6440
Controls 30 3269- - 1 1 661 2 66
Classic FRDA (cFA), point mutation FA (pFA), late onset FA (LOFA), carriers, and controls. All data are presented as mean6SD.
doi:10.1371/journal.pone.0017627.t001
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conditions reported elsewhere [4].
Quantitative real time PCR (q-PCR) of frataxin mRNA
Total mRNA was extracted from PBMCs using TRIzolH
reagent (Invitrogen) following manufacturer’s instructions. RNA
was spectrophotometrically quantified, and qualitative analysis
was performed with agarose-formaldehyde electrophoresis and
ethidium bromide staining. One mg mRNA was reversely
transcribed using the one-step High Capacity RNA-to-cDNA
Master Mix (Ambion, Applied Biosystems, Carlsbad, CA, USA)
following manufacturer’s instructions in a total volume of 20 mL.
About 2 mL of cDNA were amplified using the TaqManH Gene
Expression Master Mix and TaqManH Gene Expression Assay
for frataxin (Applied biosystems, catalog nuHs00175940_m1) in
aS t e p O n er e a l - t i m eP C R .R N Awas standardized by quanti-
fication of hypoxanthine phosphoribosyl-transferase 1 (HPRT1)
as a reference gene (Applied Biosystems, TaqManH Endogenous
controls). Relative expression was calculated with the efficiency
calibrated model [18].
Statistical Analysis
Statistical analysis for continuous variables was conducted by
one-way ANOVA. Post-hoc analysis was performed with the
Bonferroni multiple comparison’s test. Diagnostic efficacy of
frataxin dosage was assessed constructing ROC curves and
calculating area, sensitivity, specificity and P value. Correlation
analysis was performed calculating Pearson’s coefficient.
Normality tests were performed with the Kolmogorov-Smirnov
test. P values of less that 0.05 were considered statistically
significant. Analysis was performed using the Prism software
v e r s i o n5 . 0 cf o rM A C( G r a p h p a d ,L aJ o l l aC A ,U S A ) .
Quantitative-PCR data in real-time were analyzed with the
improved version of the relative expression software tool
(REST 2009) [18].
Results
Patients
A total of 38 patients were enrolled in this study. Twenty-seven
patientswerecFA,5pFA,and 6LOFA (Table 1).Patientswithpoint
mutations (Table 2) have been previously described [19,20]. Thirty-
three FRDA carriers and 30 healthy controls were also enrolled in
the study. GAA triplets were measured in all patients, carriers and
controls. One obligate carrier was found to have normal GAA
repeats on bothalleles,and one control showeda GAAexpansionon
one allele. According to their unexpected genotype, both individuals
were shifted to the correct group and further analyzed.
Table 2. Point mutation FA patients.
Patient Sex Mutation GAA repeats Age
Age at
onset
Disease
duration
Frataxin
protein pg/mg
total protein
Frataxin
protein %
Frataxin mRNA
%
1 M p.I154F 959 42 6 36 3.60 9.3 33
2 M p.I154F 921 44 13 31 5.20 13.5 48
3 M c.482+3delA 731 46 9 37 10.34 26.8 52
4 F p.R165P 988 34 4 30 21.10 54.7 67
5 F p.R165P 926 43 10 33 23.40 60.6 75
Demographics, neurological data, frataxin protein and FXN mRNA levels in pFA. Frataxin protein % and FXN mRNA levels % are expressed as relative to the control
group.
doi:10.1371/journal.pone.0017627.t002
Figure 1. Frataxin protein levels in PMBCs. Box and wiskers plot (min to max) of frataxin levels in cFA (n=24), LOFA (n=5), carriers (n=33),
controls (n=29), and pFA (n=5). Statistical significance is indicated after comparison to cFA (**p.0.01, ***p,0.001).
doi:10.1371/journal.pone.0017627.g001
Combined Screening in Friedreich Ataxia
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Mean6SD frataxin in cFA patients was 13.864.6 pg/mgt o t a l
protein, and ranged from a minimum of 6.8 to a maximum of
24.5 (Figure 1). The five point mutation patients had frataxin
levels of 12.769.1 pg/mg total protein (range 3.6–23.4; Table 2).
LOFA patients showed mean level of 25.366.9 (range 16.2–
35.5) whereas frataxin level was 26.567.1 (15.5–50.6) in
carriers and 38.667.6 (25.3–55.9) in healthy controls. Mean
residual levels of frataxin, as compared to control level, were
35.8, 33.0, 65.6, and 68.7% for cFA, pFA, LOFA, and carriers,
respectively.
Comparison of the different groups showed a significant
difference between cFA patients compared with LOFA, carriers
and controls (Figure 1; p,0.01, p,0.001, p,0.001). Similar
Figure 2. Protein correlation analysis. A) correlation between frataxin levels and GAA1 repeats in cFA and LOFA pateints (p,0.0001, R
2=0.4632);
B) correlation between frataxin levels and GAA2 repeats in cFA and LOFA patients (p,0.001, R
2=0.3886); C) correlation between frataxin levels and
age at onset for cFA and LOFA (p,0.001, R
2=0.3577); D) correlation between frataxin and GAA2 in carriers (p,0.05, R
2=0.1745); E) correlation
between frataxin levels and GAA1 in controls (p,0.05, R
2=0.1634); F) correlation between frataxin levels and GAA2 in controls (p,0.05, R
2=0.1463).
doi:10.1371/journal.pone.0017627.g002
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carriers, and controls.
Diagnostic efficiency of frataxin measurement
ROC curves were constructed to assess the efficacy of frataxin
dosage to discriminate between groups (Figure S1). Comparison of
cFA patients vs controls, resulted in a 100% sensitivity and
specificity for a cut-off frataxin value of 24.8 pg/mg total protein
(p,0.0001, area=1.00). Similar results were obtained comparing
pFA patients with controls with the same frataxin cut-off value
(p,0.001, area=1.00). Comparison of cFA patients, vs carriers
resulted in a sensitivity of 100% and specificity of 70.83% for a
cut-off value of 15.27, and a sensitivity of 66.67% and specificity of
100% for a cut-off value of 24.54 (p,0.0001, area=0.9596).
Comparison of carriers vs controls resulted in a useless sensitivity
of 100% and specificity of 45.45% for a cut-off value of 25.19
(area=0.8945).
Frataxin Correlations
For correlation analysis cFA and LOFA were considered
together (simply termed as FRDA patients). In FRDA patients,
GAA1 and GAA2 correlated inversely with frataxin levels
(p,0.0001, R
2=0.4632; P,0.001, R
2=0.3886; Figure 2A–B),
whereas age at onset correlated directly with frataxin levels
(p,0.001, R
2=0.3577; Figure 2C). In obligate carriers, we found
a mild inverse correlation between the size of the mutated
(p,0.05, R
2=0.1745; Figure 2D) but not of the wild-type (p=0.7,
R
2=0.006) allele and frataxin levels. Unexpectedly, control levels
of frataxin correlated directly with both the GAA1 and GAA2
(p,0.05, R
2=0.1634; p,0.05, R
2=0.1463; Figure 2E–F).
q-PCR of FXN mRNA
In cFA, mRNA was profoundly reduced to 19.4% of controls
(range 0.06–0.48, p,0.0001, Figure 3,) whereas there was a less
severe down-regulation in pFA (52.7% of controls, p,0.0001,
Table 2). This resulted in different mRNA relative expression
levels between cFA and pFA (p,0.001). LOFA patients and
carriers showed a less severe down-regulation to 50.4% (range
0.35–0.85, p,0.0001) and 53.0% (range 0.11–1.21, p,0.0001),
respectively. Difference was also significant when comparing
mRNA levels between cFA and LOFA (p,0.0001), or carriers
(p,0.0001). In contrast, there was no difference between LOFA or
pFA and carriers (p=0.914 and p=0.890, respectively).
Diagnostic efficiency of FXN mRNA expression
ROC curves were constructed, similarly to frataxin protein
levels, to assess the efficacy of FXN mRNA relative expression to
discriminate between groups. Comparison of cFA patients vs
controls, resulted in a 100% sensitivity and specificity for a cut-off
mRNA value of 0.6 as compared to controls (Figure S1;
p,0.0001, area=1.00). Comparison of pFA with controls resulted
in a sensitivity of 100% and specificity of 88% for a cut-off frataxin
mRNA value of 0.75 (p,0.001, area=0.976). Comparing cFA
patients vs. carriers, and carriers vs controls gave similar results as
for frataxin protein and did not reach a useful sensitivity and
specificity.
Frataxin mRNA Correlations
For mRNA correlation analysis, cFA and LOFA were
considered together (as FRDA patients). Messenger RNA levels
correlated directly with protein levels and age at onset (p,0.001,
R
2=0.4058; P,0.001, R
2=0.3905; Figure 4A–B) and inversely
with GAA1 and GAA2 sizing (p,0.01, R
2=0.2364; p,0.05,
R
2=0.1750, Figure 4C–D). We found an inverse correlation
between mRNA levels and GAA2 in carriers (p,0.0001,
R
2=0.5011; Figure 4E). Mild direct correlation was found
between mRNA and protein in carriers (p,0.02, R
2=0.2117;
Figure 4F).
Non Gaussian distributions for carriers
GAA distribution was Gaussian for all groups except for
carriers, where GAA2 was bimodal (Fig 5A). This was confirmed
using the Kolmogorov-Smirnov normality test (p,0.001), which
showed a non Gaussian distribution of GAA2. A total of seven
carriers showed ,500 GAA2 repeats influencing distribution. Of
these, four were related to LOFA patients, two were related to
cFA, and one was initially included as a control and later found to
be a carrier. A non Gaussian distribution was found for FXN
Figure 3. FXN mRNA levels in PBMC. Box and wiskers plots (min to max) of FXN mRNA relative expression levels in cFA (n=23), LOFA (n=6),
carriers (n=29), controls (n=25), and pFA (n=5). Statistical significance for all groups compared to controls is p,0.0001.
doi:10.1371/journal.pone.0017627.g003
Combined Screening in Friedreich Ataxia
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17627Figure 4. FXN mRNA correlation analysis. A) correlation between FXN mRNA and protein levels cFA and LOFA patients (p,0.001, R
2=0.4058); B)
correlation between FXN mRNA levels and age at onset in cFA and LOFA patients (p,0.0001, R
2=0.3905); C) correlation between FXN levels and
GAA1 for cFA and LOFA (p,0.01, R
2=0.2364); D) correlation between FXN levels and GAA2 for cFA and LOFA (p,0.05, R
2=0.1750); E) correlation
Combined Screening in Friedreich Ataxia
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17627mRNA levels (p,0.02; Fig 5B) and frataxin protein in carriers
(p,0.01; Fig 5C), without a clear bimodal distribution.
Discussion
We report the first combined study on frataxin protein and
mRNA levels in PBMCs from a large cohort of FRDA patients,
carriers and healthy individuals. We confirmed previous findings
of reduced levels of frataxin in FRDA patients. In our study
residual frataxin levels were 35.8% of mean control levels in cFA,
and 68.7% in carriers. These levels are slightly dissimilar to those
previously reported in FRDA patients (range 21–29%) [10–12],
and carriers (range 50.2–64%) [10,11].
In contrast absolute levels of frataxin showed considerable
differences between laboratories. In our study, FRDA patients had
average frataxin levels of 13.864.6 pg/mg total protein, which
were different to those detected by others in PBMCs (1.1–4.8 pg/
mg) [12] or lymphoblasts (127677 pg/mg) [10], or even in control
buccal swabs (30 pg/mg) [11]. This difference might be related to
different recombinant frataxin used to construct the standard
curve in the first study, or in the different cell type used in the
second study (i.e. PBMCs vs lymphoblasts, buccal swabs, or whole
blood). Thus, it seems more cautious to show data both as absolute
and relative values compared to a healthy control population for
each laboratory.
In this study, we also showed that mRNA levels were reduced to
19.4% in cFA, 50.4% in LOFA and 53% in carriers. Previous data
had reported down-regulation in cFA (16.6%), LOFA (21.5%),
and carriers (35.2%) [5]. This may be because of a different cut-off
when considering the age at onset of LOFA ($25 years in the
present study and $20 in [5]), and because of the different samples
size (5 cFA, 5 LOFA, 3 carriers and 3 controls in [5]).
Our study suggests that the absolute value of the frataxin
protein and mRNA are not the only determinant of the disease.
There was a strong overlap between groups in both protein and
mRNA expression levels. Indeed, some healthy carriers shared the
same levels with FRDA patients for both protein and mRNA, and
even more intriguingly there was a clear overlap between LOFA
and controls. It is tempting to speculate that low frataxin protein
and mRNA levels are ‘‘condicio sine qua non’’ but not the only
determinant for disease manifestations. It would be interesting to
test individuals with different genotypes (i.e. patients and carriers,
or LOFA and controls) but overlapping frataxin or mRNA levels,
and if this correlates with different cellular phenotypes.
A recent paper reported that the FXN46-210 isoform is
preferentially reduced in FRDA patients, and that the molar ratio
between the FXN46-210 and the FXN81-210 form is altered [21].
Therefore, specific measurement of these isoforms in large cohorts
of FRDA patients could be used to increase the discriminating
ability of frataxin protein measurement. Nevertheless, difference in
isoform levels should be confirmed in future studies, and it should
be further investigated weather the FXN46-210 isoform is a simple
precursor or plays a clear physiological role. In addition, data from
our study should be considered prudently since levels in PBMCs
may not be the same as in affected cells.
We report frataxin protein levels in five patients carrying three
different point mutations. The group of pFA showed a lower age at
onset when compared to cFA, despite similar frataxin protein
levels, and higher mRNA levels. Frataxin protein levels were
similar in siblings carrying the same point mutation and different
between FXN mRNA levels and GAA2 for carriers (p,0.0001, R
2=0.4667); F) correlation between FXN mRNA and protein levels in carriers (p,0.02,
R
2=0.2167).
doi:10.1371/journal.pone.0017627.g004
Figure 5. Non normal distribution of GAA2, FXN mRNA and
frataxin protein in carriers. A) Bimodal distribution of GAA2 repeats
in carriers; B) skewed distribution of FXN mRNA levels in carriers; C)
skewed distribution of frataxin protein levels in carriers.
doi:10.1371/journal.pone.0017627.g005
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study pFA carrying the p.I154F showed the lowest levels of all
tested patients, c.482+3delA had intermediate levels, and the two
p.R165P patients had the highest levels. This is confirmed by the
clinical presentation of FRDA patients carrying the p.I154F
mutation, which showed earlier onset and a more aggressive
phenotype when compared to p.R165P patients [19,20]. In
addition, higher GAA repeats were associated with lower frataxin
protein and mRNA levels between siblings harboring the p.I154F
and p.R165P mutations.
Interestingly, protein levels of all pFA were similar to cFA and
could be differentiated from controls. Conversely, mRNA levels of
pFA overlapped with carriers. This may be explained by the absence
of a pathological effect of point mutations on frataxin transcription,
while, alike carriers, the GAA expansion on the other allele reduces
mRNA efficiency. It is likely that at the protein level, a given point
mutation may affect frataxin stability reducing its level in PBMCs, as
suggested by previous studies [22]. These results are similar to other
studies that tested frataxin levels by Western blotting in lymphoblasts
from patients with different point mutations (namely, p.W173G,
c.157delC, c.100delC, p.Y118X, c.104delC) and showed reduced
protein expression (range 6.9% and 30.9% of controls) [23].
Inverse correlation was found between frataxin protein level and
GAA1 and GAA2, whereas a direct correlation was evident
between frataxin and age at onset. This is in accordance with
other studies [24]. Similar results were obtained with mRNA
measurements.
Size of GAA2 correlated inversely with frataxin levels in carriers
suggesting that, at the heterozygous state, GAA2 is able to
influence residual protein even in the presence of a normal allele.
In addition, GAA2 repeat number distribution was found to be
bimodal in carriers. This corresponded to a similar non Gaussian
frataxin mRNA and protein distribution. Although LOFA-carriers
might have contributed to the distribution, a selection bias can be
ruled out since there was not a preferential selection during
recruitment. This is the first report on GAA2 distribution on
carriers. Although preliminary and far to being predictive of the
offspring’s phenotype, it could be speculated that pathological
GAA expansions in carriers may preferentially exist in two forms.
A less frequent form (with ,500 triplets) seems to be associated
with LOFA, and a more frequent (.500 triplets) with cFA.
Surprisingly controls showed a significant positive correlation
between GAA1 and GAA2 with frataxin levels. This finding is
different from data reported by others [13] but this might be
related to differences in methodological determination of protein
dosage, or a higher dispersion of GAA sizes (2–21 in our study and
7–18 in [13] for GAA1; 2–24 in our sample and 8–26 in [13] for
GAA2) with possible ethnic differences.
In summary, we demonstrated that frataxin protein and mRNA
measurement may discriminate FRDA patients and healthy
individuals, although a few limitations to the method should be
taken into account. First, a LOFA phenotype cannot be predicted
on the basis of protein and mRNA load, at least in PBMCs, since
there was a strong overlap with carriers and controls. Second, we
and others analyzed a representative though limited number of
FRDA patients. Replicate studies on larger samples are needed
before translation of protein or mRNA measurements into daily
clinical practice. Thus, it is wiser to account on routine genetic
testing for diagnosis whereas frataxin protein and mRNA may be
attractive biomarkers for clinical trials [25–26]. Third, and
counter intuitively, frataxin protein in PBMCs seem appealing in
discriminating pFA with controls. Compared to the more
expensive and laborious gene sequencing or Western blotting,
the use of lateral-flow immunoassay in PBMCs can be proposed
prior to full FXN sequencing if genetic testing reveals a
heterozygous expansion, family history is dark, and clinical
symptoms are not fully manifested.
Supporting Information
Figure S1 ROC curves of frataxin and FXN mRNA. ROC
curves showing specificity and sensitivity of frataxin measurement
to discriminate between groups using frataxin protein measure-
ment (A-D) or mRNA (E-H). A) cFA compared to controls; B) pFA
compared to controls; C) cFA compared to controls; and D)
carriers compared to controls; E) cFA compared to controls; F)
pFA compared to controls; G) cFA compared to LOFA; and H)
carriers compared to controls.
(PDF)
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